期刊文献+

精神分裂症患者血清miR-132-3p和miR-34a-5p表达水平与认知功能以及诊断的相关性研究 被引量:6

Correlation Study of Serum miR-132-3p and miR-34a-5p Expression Levels with Cognitive Function and Diagnosis in Patients with Schizophrenia
下载PDF
导出
摘要 目的探讨血清微小核糖核酸(micro RNA,miR)-132-3p,miR-34a-5p表达与精神分裂症患者认知功能的关系,分析其诊断精神分裂症的价值。方法选择2019年2月~2021年10月武汉钢铁(集团)公司第二职工医院收治的208例精神分裂症患者(精神分裂症组)和同期71例健康体检者(对照组)。检测血清miR-132-3p和miR-34a-5p表达,Pearson相关性分析其与精神分裂症患者阳性和阴性症状量表(positive and negative symptom scale,PANSS)、精神分裂症认知功能成套测验(采用MATRICS consensus cognitive battery,MCCB)、Stroop色词测验评分相关性。受试者工作特征(receiver operating characteristic,ROC)曲线分析miR-132-3p和miR-34a-5p诊断精神分裂症的价值。结果精神分裂症组血清miR-132-3p(3.26±0.84),miR-34a-5p(5.02±1.39)表达均高于对照组(1.05±0.33,1.62±0.5),差异有统计学意义(t=21.782,20.276,均P<0.05);精神分裂症组MCCB,Stroop色词测验评分均低于对照组(t=6.651~16.778,均P<0.05)。精神分裂症患者血清miR-132-3p,miR-34a-5p表达与PANSS总分呈正相关(r=0.502,0.477,均P<0.05),与连线测验、持续操作测验、语言记忆、Stroop单词测验评分呈负相关(r_(miR-132-3p)=-0.501~-0.368,r_(miR-34a-5p)=-0.483~-0.317,均P<0.05)。miR-132-3p,miR-34a-5p诊断精神分裂症的最佳截断值为2.16,3.35,曲线下面积为0.694,0.712,联合miR-132-3p和miR-34a-5p诊断精神分裂症的曲线下面积为0.895,大于单独miR-132-3p,miR-34a-5p诊断(Z=5.747,5.665,均P<0.05)。结论miR-132-3p和miR-34a-5p表达上调,与精神分裂症症状加重以及认知功能受损有关,miR-132-3p和miR-34a-5p联合检测在精神分裂症诊断中具有较高价值。 Objective To investigate the relationship between the expression of serum miR-132-3p and miR-34a-5p and the cognitive function of patients with schizophrenia,and analyze its diagnostic value of schizophrenia.Methods 208 schizophrenic patients(schizophrenia group)admitted to the Second Staff Hospital of Wuhan Iron and Steel(Group)Company from February2019 to October 2021 were selected,and in addition,71 healthy patients in the hospital were selected as the control group.The expressions of serum miR-132-3p and miR-34a-5p were detected,and Pearson correlation analysis was conducted for their correlation with positive and negative symptom scale(PANSS),Schizphrenia cognitive function siute test(adopt MCCB)and Stroop color word test scores.Receiver operating characteristic curve(ROC)analyzed the value of miR-132-3p and miR-34a-5p in diagnosis of schizophrenia.Results The levels of miR-132-3p(3.26±0.84)and miR-34A-5p(5.02±1.39)in schizophrenia group were higher than those in control group(3.26±0.84 vs 1.05±0.33,5.02±1.39 vs 1.62±0.42),the differences were statistically significant(t=21.782,20.276,all P<0.05).MCCB and Stroop test scores were lower than control group(t=6.651~16.778,all P<0.05).The expression of miR-132-3p and miR-34a-5p was positively correlated with the total score of PANSS in schizophrenia patients(r=0.502,0.477,all P<0.05),and was negatively correlation with the score of connection test,continuous operation test,verbal memory and Stroop word test(r_(miR-132-3p)=-0.501~-0.368,r_(miR-34a-5p)=-0.483-~0.317,all P<0.05).The optimal truncation values of miR-132-3p and miR-34a-5p for the diagnosis of schizophrenia were2.16 and 3.35,and the area under the curve were 0.694 and 0.712.The area under the curve for the diagnosis of schizophrenia by combining miR-132-3p and miR-34A-5p was 0.895,which were higher than miR-132-3p and miR-34a-5p alone(Z=5.747,5.665,all P<0.05).Conclusion The upregulation of miR-132-3p and miR-34a-5p was associated with the aggravation of schizophrenia symptoms and impaired cognitive function,and the combination of miR-132-3p and miR-34A-5p has a high value in the diagnosis of schizophrenia.
作者 钱博文 王皓 钟志延 刘春艳 QIAN Bo-wen;WANG Hao;ZHONG Zhi-yan;LIU Chun-yan(Department of Psychiatry,the Second Staff Hospital of Wuhan Iron and Steel(Group)Company,Wuhan 430080,China)
出处 《现代检验医学杂志》 CAS 2023年第1期33-37,共5页 Journal of Modern Laboratory Medicine
基金 武汉市卫生计生委科研项目(WJ20195036),资助单位:武汉市卫生计生委。
关键词 miR-132-3p miR-34a-5p 精神分裂症 认知功能 miR-132-3p miR-34a-5p schizophrenia cognitive function
  • 相关文献

参考文献4

二级参考文献24

  • 1Yamashita C, Mizuno M, Nemoto T, et al. Social cognitive problem-solving in schizophrenia: associations with fluency and verbal memory. Psychiatry Res, 2005, 134 : 123-129.
  • 2Penades R, Boget T, Catalon R, et al. Cognitive mechanisms, psychosocial functioning, and neurocognitive rehabilitation in schizophrenia. Schizophr Res, 2003,63:219-227.
  • 3Marder SR, Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res, 2004, 72:5-9.
  • 4Kern RS, Green MF, Nuechterlein KH, et al. NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophr Res, 2004,72:11-19.
  • 5Green MF, Nueehterlein KH. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res, 2004, 72 : 1-3.
  • 6Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry, 2004,56:301-307.
  • 7Nuechterlein KH, Barch DM, Gold JM, et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res, 2004, 72:29-39.
  • 8Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1 : test selection, reliability, and validity. Am J Psychiatry, 2008,165:203-313.
  • 9Kern RS, Nuechterlein KH, Green MF, et al. The MATRICS Consensus Cognitive Battery, part 2 : eo-norming and standardization. Am J Psychiatry, 2008,165:214-220.
  • 10Nuechterlein KH, Green MF. MCCB Manual. Los Angeles: MATRICS Assessment, 2006 : 17-28.

共引文献777

同被引文献81

引证文献6

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部